AstraZeneca (AZN) officer Mani Sharma details share and award holdings

Rhea-AI Filing Summary

ASTRAZENECA PLC officer Mani Sharma filed an initial insider ownership report, listing current equity and award holdings in the company. Sharma directly holds 31,153.4659 ordinary shares, plus equity awards that may convert into additional shares over time.

The filing shows 2,996.3080 restricted stock units, each representing a right to receive one ordinary share that vests on November 16, 2028, with shares to be delivered on November 17, 2028. There are also 31.2970 dividend equivalent rights, which accrue on these RSUs and convert into ordinary shares on the same vesting date.

In addition, Sharma holds an employee stock option covering 195 ordinary shares at an exercise price of $123.9800 per share, exercisable from December 1, 2028 until June 1, 2029. The exercise price is originally denominated at GBP93.64, with the reported dollar value based on a stated exchange rate.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sharma Mani

(Last) (First) (Middle)

C/O ASTRAZENECA PLC 1 FRANCIS

CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE CB2 0AA

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	31,153.4659	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	(1)	Ordinary Shares	2,996.308	(1)	D
Dividend Equivalent Rights	(2)	(2)	Ordinary Shares	31.297	(2)	D
Employee Stock Option (right to buy)	12/01/2028	06/01/2029	Ordinary Shares	195	$123.98(3)	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. The RSUs vest on November 16, 2028. Vested ordinary shares will be delivered to the reporting person on November 17, 2028.

2. Dividend equivalent rights accrue on the reporting person's RSUs when and as dividends are paid on the Issuer's ordinary shares and vest along with the RSUs on which they accrued. Each dividend equivalent right converts into one ordinary share of the Issuer on the date of vesting.

3. The exercise price for these options under the Issuer's Savings Related Share Option Scheme is denominated in British pounds sterling at a price of GBP93.64 per ordinary share. The exercise price reported herein was converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3240 on March 13, 2026 as published by the Board of Governors of the Federal Reserve System. The exercise price is the actual British pounds sterling amount regardless of the exchange rate on the date of exercise.

Remarks:

SVP, Group Controller and Head of Global Finance Services

	/s/ Mani Sharma	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Mani Sharma’s Form 3 filing for AstraZeneca (AZN) show?

The filing shows Mani Sharma’s initial insider ownership in AstraZeneca, including 31,153.4659 ordinary shares, 2,996.3080 restricted stock units, 31.2970 dividend equivalent rights, and options on 195 shares at a fixed exercise price. It reports existing holdings, not new market purchases or sales.

How many AstraZeneca (AZN) ordinary shares does Mani Sharma directly hold?

Mani Sharma directly holds 31,153.4659 AstraZeneca ordinary shares. This figure reflects current direct share ownership reported in the Form 3, separate from restricted stock units, dividend equivalent rights, and employee stock options that may convert into additional shares in the future under specific vesting or exercise conditions.

When do Mani Sharma’s AstraZeneca (AZN) restricted stock units vest?

Mani Sharma’s restricted stock units vest on November 16, 2028. Each unit represents a right to receive one AstraZeneca ordinary share, with the vested shares scheduled for delivery on November 17, 2028. Dividend equivalent rights tied to these units vest and convert into ordinary shares on the same date.

What stock options does Mani Sharma hold in AstraZeneca (AZN)?

Mani Sharma holds an employee stock option over 195 AstraZeneca ordinary shares at an exercise price of $123.9800 per share. The option is exercisable from December 1, 2028, until June 1, 2029, and the price is originally set in British pounds and translated into U.S. dollars.

How are dividend equivalent rights treated in Mani Sharma’s AstraZeneca (AZN) holdings?

Dividend equivalent rights accrue on Mani Sharma’s restricted stock units when AstraZeneca pays dividends on ordinary shares. These rights vest alongside the underlying RSUs and each converts into one ordinary share on the vesting date, providing share-based compensation aligned with dividend payments over time.